Best Grants for Cancer Nonprofits in Guam

Bristol Myers Squibb is dedicated to enhancing healthcare and advancing scientific knowledge through its Corporate Giving program. By supporting various organizations, BMS aims to improve health equity and access to essential medicines for underserved populations. Their focus includes charitable donations, medical education, and community support initiatives. This commitment reflects BMS's goal to make a positive impact on patients' lives and foster strong communities where their employees work and live.

The Scott R. MacKenzie Foundation offers grants to support innovative genetic research aimed at advancing cures for diseases like cancer, diabetes, lung, and heart diseases. Only U.S.-based tax-exempt organizations with over five years of operation can apply. The Foundation emphasizes collaboration among research entities to enhance genome sequencing and disease detection. By funding these initiatives, they aim to foster awareness and progress in genetic research for future generations.

The McKesson Foundation Grant provides funding above $25,000 to support health equity initiatives across North America. Founded in 1943, its mission focuses on removing barriers to quality healthcare for vulnerable communities. The foundation prioritizes projects that align with strategic pillars: reducing cancer burdens, preparing the healthcare workforce, and enhancing crisis response. Eligible organizations include national and local nonprofits. Funding is limited to specific regions and assessed based on demonstrated need and expected impact.

The Elsa U. Pardee Foundation has been a pioneer in cancer research funding since 1944, providing over $110 million to more than 300 institutions across the U.S. It supports innovative approaches by both new and established researchers, ensuring diverse ideas receive necessary funding. Additionally, the Foundation addresses immediate financial needs for cancer patients, allocating about one-third of its grants to assist those in need. This dual focus on research and patient support distinguishes the Foundation in the fight against cancer.

The Barney Family Foundation Grant focuses on improving early education and advancing medical research, particularly in cancer and Alzheimer’s. It supports organizations that demonstrate a clear plan to enhance children's life experiences and educational opportunities for those in grades K-8. Grants typically range from $5,000 to $50,000, prioritizing established entities while welcoming startups. Eligible applicants must have 501(c)(3) status, and the Foundation does not fund individual requests or political activities.

The Brees Dream Foundation Grant aims to enhance the lives of cancer patients while providing essential care, education, and opportunities for children and families in need. With the support of generous donors and partners, the Foundation is dedicated to advancing cancer research and offering vital resources to those facing challenges. This commitment reflects a profound dedication to improving quality of life and fostering hope in communities.

Sanofi Philanthropic Donations support non-profit organizations aligned with Health Equity, STEM Education Equity, and Local Communities. Applications are accepted year-round, with a review process of 8 to 16 weeks. The initiative focuses on improving healthcare access, fostering innovation, and addressing social determinants of health. Sanofi emphasizes collaboration and sustainable solutions, advocating for equal opportunities in health and education, and nurturing future talent to tackle medical challenges.

The Prevent Cancer Foundation is launching a $100,000 community grant program for 2024-2026, focusing on patient navigation for cancer prevention and early detection. Community-based organizations can apply for funding over two years to enhance their efforts. Priority will be given to applicants demonstrating best practices, established community partnerships, and initiatives that address health disparities. Note that the application cycle opens in 2026, emphasizing the importance of proactive health measures.

Exelixis Grants & Giving focuses on impactful charitable contributions, supporting non-profit organizations in community support, healthcare-related initiatives, independent patient assistance, medical education, and sponsorships. Their aim is to enhance oncology care, particularly for renal cell carcinoma and other cancer types, while ensuring proposals are submitted within specified timelines. Exelixis partners with organizations dedicated to improving patient outcomes and community health, demonstrating their commitment to making a difference beyond medicine.

The ASTRO Medical Student Fellowship Award for Underrepresented Populations aims to enhance diversity in radiation oncology by supporting medical students from underrepresented backgrounds. Awardees receive a $6,000 package, including a stipend for an eight-week training program, funds for travel expenses, and mentorship opportunities. This initiative is part of ASTRO's broader mission to advance patient care and professional development in the field of radiation oncology, fostering an inclusive environment in medical education.

The Myelodysplastic Syndromes (MDS) Research Fund Grant, established by the Vera and Joseph Dresner Foundation, aims to enhance research and treatment of MDS and related blood disorders. This fund supports innovative projects addressing etiology, biology, genetics, prognosis, treatment, symptom management, and quality of life. It offers up to $125,000 for Early Career Awards and $250,000 for Established Investigator Awards, facilitating significant advancements in the field.

The Melanoma Career Development Award (CDA) is offered by the Melanoma Research Foundation to support researchers dedicated to melanoma and its prevention. This award is designed for postdoctoral fellows with under five years of experience, research associates, scientists, staff scientists, assistant professors, and those focusing on melanoma prevention. The initiative promotes innovative research to advance understanding and treatment of melanoma, ultimately aiming to reduce its impact.

The Fogarty Emerging Global Leader Award supports early career research scientists from low- or middle-income countries (LMIC) by providing research funding and mentored career development for three to five years. This program encourages LMIC scientists in health-related fields to develop projects aligned with their country's health priorities, fostering independent research careers within their institutions. Applications are welcomed from junior faculty members, enhancing global health research and capacity in LMICs.

The Extramural Discovery Science Accelerator Award supports the commercialization of ongoing cancer research projects, focusing on experiments that facilitate technology validation and de-risking. Applications are accepted on a rolling basis, with a budget of up to $75,000 for one year. This award encourages independent investigators at any career stage to advance their technologies, with a strong emphasis on commercial viability and collaboration within a learning community.

This grant aims to enhance applied regulatory science research for the evaluation and treatment of cardiotoxicity associated with oncology therapeutics. The initiative will facilitate collaboration with the FDA to develop effective methodologies and solutions, ensuring that research outcomes are directly relevant to regulatory decision-making. Key activities include regular communication with funded investigators and a focus on improving detection and management of cardiotoxicity, ultimately leading to impactful publications and presentations.

The 2026 Vilcek Prizes for Creative Promise in Biomedical Science will award three $50,000 prizes to exceptional young immigrant scientists in the U.S. This prestigious prize recognizes innovative research contributions in biomedical science. Eligible candidates must be under 38 years old, hold a doctoral degree, and have made significant achievements in their field. The Vilcek Foundation aims to highlight the impact of immigrant scientists on the advancement of biomedical research, fostering diversity and excellence.

The ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant aims to enhance the research careers of residents and fellows focused on radiation oncology, specifically benefiting lung cancer patients. This initiative supports basic, translational, and clinical research endeavors. With a maximum award amount of $50,000 for one year, it provides essential funding to foster innovative projects that can lead to significant advancements in lung cancer treatment.

The Postdoctoral Grant Program at the University of Wisconsin School of Medicine and Public Health aims to support the growth and professional development of postdoctoral trainees, fellows, and associates. With funding up to $20,000 for one year, recipients can engage in independent research projects, attend workshops, or cover open-access publication fees. This initiative enhances research capacity and promotes health equity in Wisconsin, addressing critical health challenges while fostering career advancement in the medical field.

The ASTRO-AstraZeneca SCLC Therapy Challenge RFP aims to enhance research on limited-stage small cell lung cancer (LS-SCLC) through innovative combination therapies, particularly integrating immunotherapy with advanced radiation techniques. Proposals are encouraged to explore various aspects, including care patterns, treatment workflows, prognostic biomarkers, and toxicity management. The target budget for projects ranges from $175,000 to $375,000, with consideration given to higher requests based on scientific merit, fostering significant advancements in radiation oncology.

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.NCORP will support the following components that will be individually awarded through the respective RFAs indicated below:

• NCORP Research Bases (UG1 Clinical Trials Required);
• NCORP Community Sites (UG1 Clinical Trials Not Allowed); and
• NCORP Academic Community Sites (UG1 Clinical Trials Not Allowed)

NCORP Community Sites are consortia of community hospitals and/or oncology practices, which may or may not be formally affiliated in a healthcare system, that accrues participants to cancer control, prevention, treatment and care delivery clinical trials and other human subjects research.

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery. NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:

• NCORP Research Bases (UG1 Clinical Trials Required);
• NCORP Community Sites (UG1 Clinical Trials Not Allowed); and
• NCORP Academic Community Sites (UG1 Clinical Trials Not Allowed)

The RFA: Biology to Prevention Award (CRUK) aims to foster innovative translational research that enhances understanding of cancer biology, ultimately leading to effective prevention strategies. Joint applications from UK and US research teams are encouraged, with a focus on equal partnerships and complementary expertise. The funding provides up to £600,000 for UK costs and up to $946,000 for US costs, supporting projects of 1 to 5 years duration that address critical research questions in cancer prevention.

The Anna Fuller Fund Grant provides year-round support for organizations dedicated to alleviating suffering caused by cancer. Established in memory of Egbert C. Fuller’s wife, the fund prioritizes applications that focus on cancer research and education initiatives. Eligible applicants must be 501(c)(3) organizations or equivalent charities outside the U.S. Grant funds cannot be used for direct treatment, ensuring that resources are allocated to research and public education.

The James Paul Sutton Medical Research Fund Grant supports non-profit organizations engaged in cancer and medical research, established through a trust by the Sutton family. Eligible organizations must be 501(c)(3) exempt. Preference is given to cancer research initiatives, while grants are not available for individuals, political groups, or for-profit entities. This fund aims to sustain medical research efforts for the long term, continuing the legacy of the Sutton family.

The Simeon J. Fortin Charitable Foundation, founded in 1986, champions cancer research initiatives aimed at finding a cure. It supports relevant projects and fellowships within medical and research institutions, ensuring a significant impact on health-related research. The grant review process is conducted by The Medical Foundation, in coordination with the King Trust Postdoctoral Fellowships, enhancing collaboration and funding opportunities for innovative research in oncology.

The AGD Foundation Grant Program supports nonprofit organizations in the U.S. and Canada that provide free oral cancer screenings and education, particularly for underserved communities. Established in 1972, the AGD Foundation aims to enhance public oral health and raise awareness about oral/oropharyngeal cancer. By promoting early detection and education, the foundation seeks to improve survival rates and empower communities. Eligible applicants must be 501(c)(3) organizations demonstrating a commitment to community health.

The grant program by Pfizer, Inc. aims to enhance the knowledge of Advanced Practice Providers (APPs) in the field of biomarker and genetic testing for cancer. By providing educational resources and programs, this initiative seeks to empower APPs to make informed treatment decisions in oncology, ultimately improving patient outcomes. This program encourages applications that address the specific educational needs of APPs, particularly in using biomarkers for targeted therapies.